Myriad Genetics and Gabbi Partner to Advance Breast Cancer Risk Assessment
Collaboration enhances breast cancer risk assessment with genetic testing and specialist access for high-risk patients.
Myriad Genetics, Inc. (NASDAQ: MYGN) has announced a strategic collaboration with Gabbi, a telehealth platform specializing in breast cancer risk assessment and specialist care. This partnership will integrate Gabbi’s risk assessment tools with Myriad’s MyRisk® with RiskScore® Hereditary Cancer Test, providing a seamless process for identifying high-risk patients and connecting them with genetic testing and personalized care plans. The initiative aims to enhance early detection and prevention strategies for women at risk of hereditary breast cancer.
Gabbi’s mission is deeply personal for Founder and CEO Kaitlin Christine, who lost her mother to breast cancer and later received her own diagnosis. She emphasized the importance of genetic testing in empowering women to take proactive steps in their healthcare journey. Melissa Gonzales, President of Myriad Women’s Health, highlighted how this partnership aligns with Myriad’s commitment to providing women with actionable health insights. By integrating risk assessment, telehealth access, and genetic testing, this collaboration enhances breast cancer prevention and early detection efforts.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Altro da Pharma News
Tutti gli articoli →
Medicus Pharma presenta all’FDA il protocollo di fase 2b/3 per Teverelix
Fresenius Kabi Riceve una Lettera di Richiamo dalla FDA dopo Fallimenti nelle Indagini sul Processo Asettico presso lo Stabilimento di Melrose Park
Discussion